AbbVie (ABBV) Research & Development (2012 - 2026)
AbbVie (ABBV) posted quarterly Research & Development of $2.5 billion for Q1 2026, up 19.59% year-over-year from $2.1 billion in Q1 2025, and down 4.15% quarter-over-quarter from $2.6 billion in Q4 2025.
AbbVie (ABBV) Research & Development (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Research & Development for 15 consecutive years, with $2.5 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 19.59% year-over-year to $2.5 billion; the TTM figure through Mar 2026 stood at $9.5 billion (down 26.46% YoY), while the FY2025 annual figure was $9.1 billion, down 28.89% from the prior year.
- Research & Development fell to $2.5 billion in Q1 2026 per ABBV's latest filing, from $2.6 billion in the prior quarter.
- Across five years, Research & Development topped out at $6.8 billion in Q4 2024 and bottomed at $1.5 billion in Q1 2022.
- Historically, Research & Development has averaged $2.3 billion across 5 years, with a median of $1.9 billion in 2024.
- Annual changes were most pronounced in 2024 — Research & Development soared 251.53% — and 2025, when it sank 61.93%.
- AbbVie's Research & Development stood at $1.8 billion in 2022, then climbed by 7.65% to $1.9 billion in 2023, then jumped by 251.53% to $6.8 billion in 2024, then tumbled by 61.93% to $2.6 billion in 2025, then decreased by 4.15% to $2.5 billion in 2026.
- Business Quant data shows ABBV's Research & Development at $2.5 billion in Q1 2026, $2.6 billion in Q4 2025, and $2.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 2.85 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 4.05 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -4.65 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -2.60 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.34 Bn |
| Mar 31, 2026 | 2.47 Bn |
| Dec 31, 2025 | 2.58 Bn |
| Sep 30, 2025 | 2.32 Bn |
| Jun 30, 2025 | 2.13 Bn |
| Mar 31, 2025 | 2.07 Bn |
| Dec 31, 2024 | 6.77 Bn |
| Sep 30, 2024 | 2.13 Bn |
| Jun 30, 2024 | 1.95 Bn |
| Mar 31, 2024 | 1.94 Bn |
| Dec 31, 2023 | 1.93 Bn |
| Sep 30, 2023 | 1.72 Bn |
| Jun 30, 2023 | 1.73 Bn |
| Mar 31, 2023 | 2.29 Bn |
| Dec 31, 2022 | 1.79 Bn |
| Sep 30, 2022 | 1.61 Bn |
| Jun 30, 2022 | 1.61 Bn |
| Mar 31, 2022 | 1.50 Bn |
| Dec 31, 2021 | 1.83 Bn |
| Sep 30, 2021 | 1.66 Bn |